

Supplementary Table 1. Baseline Characteristics of patients with MS/CIS

| | IA | PE | Total | p |
|--|------------------|------------------|------------------|------|
| Patients (cycles) | 72 (100) | 21 (27) | 93 (127) | |
| Age (years) | 41.5 (29.0–49.0) | 38.0 (29.0–40.5) | 40.0 (29.0–49.0) | 0.23 |
| Sex | | | | 1.00 |
| male | 19 (26.4 %) | 5 (23.8 %) | 24 (25.8 %) | |
| female | 53 (73.6 %) | 16 (76.2 %) | 69 (74.2 %) | |
| BMI (kg/m²) | 24.0 (21.2–27.9) | 23.9 (21.0–26.4) | 23.9 (21.3–27.6) | 0.74 |
| Age at Onset (years) | 28.5 (23.8–39.0) | 29.0 (17.0–37.0) | 29.0 (22.5–38.0) | 0.71 |
| Age at Diagnosis (years) | 30.5 (25.0–39.3) | 29.5 (22.0–39.0) | 30.0 (25.0–39.0) | 0.70 |
| Time between Relapse and IA/PE (days) | 70 (36–136) | 46 (11–375) | | 0.88 |
| Disease-modifying Therapies | | | | |
| Interferon | 16 (22.2%) | 2 (9.5%) | 18 (19.4%) | |
| Glatiramer acetate | 12 (16.7%) | 2 (9.5%) | 14 (15.1%) | |
| Fingolimod | 16 (22.2%) | 2 (9.5%) | 18 (19.4%) | |
| Natalizumab | 8 (11.1%) | 2 (9.5%) | 10 (10.8%) | |
| Teriflunomid | 5 (6.9%) | 1 (4.8%) | 6 (6.5%) | |
| Dimethyl fumarate | 5 (6.9%) | 3 (14.3%) | 8 (8.6%) | |

IA – immunoadsorption; PE – plasma exchange; BMI – body mass index

Supplementary Table 2. Baseline Characteristics of patients with CIDP

| | IA | PE | Total | p |
|---------------------------------|------------------|------------------|------------------|------|
| Patients (cycles) | 30 (80) | 4 (18) | 34 | |
| Age (years) | 61.5 (54.8–71.5) | 78.0 (61.0–79.0) | 62.0 (55.0–74.0) | 0.15 |
| Sex | | | | 0.55 |
| male | 21 (70.0%) | 4 (100.0%) | 25 (73.5 %) | |
| female | 9 (30.0%) | 0 (0.0%) | 9 (26.5 %) | |
| BMI (kg/m²) | 26.2 (24.1–30.9) | 24.8(22.6–43.1) | 26.1 (23.8–30.9) | 0.69 |
| Age at Onset (years) | 53.0 (46.3–64.8) | 61.5 (60.0–63.0) | 54.5 (48.8–64.0) | 0.33 |
| Age at Diagnosis (years) | 54.0 (48.0–67.0) | 70.0 (70.0–79.0) | 60.0 (50.8–70.8) | 0.08 |
| Previous Therapies | | | | |
| Prednisolone | 20 (66.7%) | 3 (75.0%) | 23 (67.6%) | |
| IVIg | 24 (80.0%) | 3 (75.0%) | 27 (90.0%) | |
| Azathioprine | 3 (10.0%) | 0 (0.0%) | 3 (8.8%) | |
| Methotrexate | 1 (3.3%) | 0 (0.0%) | 1 (2.9%) | |

IA – immunoadsorption; PE – plasma exchange; BMI – body mass index; IVIg – intravenous immunoglobulines

Supplementary Table 3. Baseline Characteristics of patients with GBS

| | IA | PE | Total | p |
|-------------------------------|------------------|------------------|------------------|------|
| Patients (cycles) | 17 (22) | 10 (15) | 27 | |
| Age (years) | 52.0 (36.0–63.0) | 66.0 (60.5–73.0) | 61.0 (39.0–70.5) | 0.07 |
| Sex | | | | 1.00 |
| male | 7 (41.2%) | 4 (40.0%) | 11 (40.7 %) | |
| female | 10 (58.8%) | 6 (60.0%) | 16 (59.3 %) | |
| BMI (kg/m²) | 22.3 (21.3–25.2) | 27.0 (19.5–29.2) | 23.5 (21.2–26.6) | 0.12 |

IA – immunoadsorption; PE – plasma exchange; BMI – body mass index; IVIg – intravenous immunoglobulines